Capivasertib (Truqap) – targeted treatment in selected breast cancer cases

What capivasertib is in simple patient language

Truqap – brand name. Capivasertib – the drug name in medical records. A cancer tablet. A targeted drug. Not a chemo drip. Not immunotherapy. Not a tablet to start just because the report says breast cancer.

Why it comes up: some breast cancers still listen to estrogen, but they also use a busy inner growth road. That road can involve PI3K, AKT, or PTEN. Truqap presses on the AKT part of the route.

Most often the discussion is not about capivasertib alone. It is about capivasertib together with fulvestrant. The doctor checks whether the cancer story, the receptor results, the molecular report, blood sugar, liver values, skin history, and daily strength all fit.

How capivasertib works

Cancer cells do not grow from one message only. In some breast cancers, the hormone route is still important, but another inner signal keeps pushing the cell forward.

Capivasertib blocks AKT. In plain words, it makes one of the cancer cell’s growth signals less comfortable. It does not “burn out” the tumor. It tries to make the endocrine plan more useful in the right setting.

That is why the mutation report matters. If the useful entrance point is not there, the tablet may look attractive on paper but not make sense for this patient.

Which diseases capivasertib may be used for

Capivasertib is not a general breast cancer tablet. It is discussed in a narrower situation, after the doctor has checked the biology of the tumor and the previous treatment path.

• breast cancer that still has an estrogen-driven part;
• HER2 is not the main target in the current plan;
• the disease has already moved on after endocrine treatment or returned too soon after it;
• the molecular report shows a relevant PIK3CA, AKT1, or PTEN change;
• fulvestrant is a reasonable partner for this step;
• second opinion when Truqap was offered and the reason is not fully clear.

Same breast cancer label. Different patient. Different answer. Bone-only disease, liver spots, fast symptoms, diabetes, rash history, earlier CDK4/6 therapy, and how quickly the cancer moved can all change the plan.

When capivasertib can be especially relevant

The drug usually enters the conversation after endocrine treatment no longer holds the disease well enough. The doctor is not only asking, “Can we give another tablet?” The real question is, “Does this tumor have the signal we can use?”

• the cancer is still in the hormone-sensitive group, but older endocrine control is no longer enough;
• a molecular test found a change in the PI3K-AKT-PTEN area;
• the patient already had a CDK4/6 inhibitor and the next step needs review;
• the disease needs a systemic plan, not only local treatment to one spot;
• blood sugar, skin risk, diarrhea risk, and liver values can be followed safely;
• the family wants to compare this plan with chemotherapy, another targeted drug, or a trial.

The point is not that Truqap is new. The point is whether it has a job now: hold the disease, delay a harsher step, add strength to fulvestrant, or give time with a tolerable plan.

What needs to be checked before treatment

One short note is not enough. The doctor needs the tumor file and the patient file together.

• current ER, PR, and HER2 results;
• full molecular report, not only one copied line;
• which genes were tested and whether PIK3CA, AKT1, and PTEN were included;
• all previous breast cancer treatments, dates, response, and reason for stopping;
• where the disease is now: bone, liver, lung, lymph nodes, or another site;
• recent CT, MRI, PET-CT, bone scan, or the scans used in this case;
• fasting glucose, HbA1c, diabetes or prediabetes history;
• liver and kidney values, CBC, and general chemistry;
• past severe rash, mouth sores, diarrhea, allergy, or dehydration;
• regular medicines, including diabetes drugs, steroids, antibiotics, sleep pills, pain tablets, herbs, and supplements;
• menstrual status, ovarian suppression plan, and pregnancy questions when relevant.

Sometimes the start waits. Not because the idea is wrong. Because sugar is too high, the rash risk is not understood, diarrhea is already active, or the molecular report is too incomplete to trust.

How treatment with capivasertib goes

Truqap is taken by mouth on a schedule with treatment days and break days. Fulvestrant is given separately by injection. The patient should not copy a schedule from another person or restart tablets after a pause by guess.

The first weeks are not only about scans. They show whether the body can live with the plan. Stool. Skin. Mouth. Thirst. Urination. Weakness. Appetite. Sugar numbers. Those details matter early.

During treatment, the team usually follows:

• blood sugar and HbA1c when needed;
• diarrhea count, drinking, dizziness, and dry mouth;
• rash, itching, peeling, blisters, or mouth sores;
• liver values, kidney values, and CBC;
• appetite, nausea, vomiting, weight, and daily strength;
• disease trend on scans and symptoms;
• new medicines added by any other doctor.

A side effect does not always mean the treatment failed. It may mean a pause, fluids, diarrhea medicine, skin treatment, sugar control, or a dose discussion. The patient should not build that plan alone.

Possible side effects

People do not all get the same problem. One person mainly gets loose stool. Another gets rash. Another has high sugar. Another just feels washed out.

What can appear:

• loose stool, sometimes quickly becoming hard to manage;
• rash, redness, itching, peeling, or painful skin;
• higher blood sugar, stronger thirst, frequent urination, heavy sleepiness;
• nausea, vomiting, low appetite, belly discomfort;
• mouth soreness or inflamed gums;
• tiredness and loss of strength;
• changes in blood tests or chemistry;
• dehydration when diarrhea or vomiting is not handled early.

Do not wait until the symptom becomes dramatic. With this drug, early reporting can keep a small problem from becoming the reason treatment has to stop.

When the treating team needs to know fast

Call the treating team the same day if something like this starts:

• loose stool again and again, especially with weakness, thirst, dizziness, or dry mouth;
• rash spreading fast, skin pain, blisters, peeling, or sores in the mouth;
• strong thirst, very frequent urination, confusion, heavy sleepiness, or feeling suddenly unlike yourself;
• fever, chills, sore throat, cough, or another infection sign;
• repeated vomiting or not being able to drink;
• yellow eyes or skin, dark urine, or strong pain under the right ribs;
• face swelling, breathing trouble, or a sudden allergic-type reaction;
• a quick drop in general condition after starting or changing the plan.

Do not sit at home trying to decide whether Truqap caused it. The team can sort that out. The patient’s job is to report the change early.

Why capivasertib is not right for everyone

Capivasertib can be useful in the right case. It is still not a universal tablet for every hormone-related breast cancer.

• the needed molecular change is not found or the report is incomplete;
• HER2 or another target now drives the treatment choice more strongly;
• the disease is moving so fast that another approach is needed first;
• blood sugar is already unsafe or diabetes is not controlled;
• diarrhea, dehydration, or severe weakness is present before treatment;
• there was a serious skin reaction in the past and the risk is too high;
• liver values or general condition do not allow this step safely;
• another treatment gives a better balance for this moment.

Choosing another plan does not mean Truqap is a bad drug. It may simply be the wrong tool for this patient now.

Can capivasertib be combined with other treatments

The usual discussion is capivasertib with fulvestrant. Other pieces of the plan depend on the disease sites, symptoms, and what has already been tried.

• fulvestrant as the endocrine partner;
• ovarian suppression when the patient is not fully postmenopausal and the doctor needs that control;
• bone-strengthening medicine when bone disease calls for it;
• radiation to a painful or risky spot when local help is needed;
• support for diarrhea, rash, mouth pain, nausea, sugar, or dehydration;
• clinical trial discussion if standard options are becoming narrow.

Do not add supplements, herbs, diabetes changes, steroids, antibiotics, or “skin pills” without telling the oncology team. A small change outside oncology can confuse the safety picture.

What no quick response can mean

A fast shrinkage is not guaranteed. Sometimes the best early sign is quieter symptoms or no new growth. Sometimes the first lesson is simply whether diarrhea, rash, and sugar can be controlled.

The doctor does not judge by one feeling. Scans, pain, liver tests, markers if used, appetite, sugar, side effects, and the pace before treatment all matter.

Waiting forever is not a plan either. If symptoms grow, scans worsen, or toxicity becomes unsafe, the discussion has to move on.

Oncology consultation in Israel about capivasertib

At Tel Aviv Medical Clinic, a patient can review whether Truqap has a real place in the current breast cancer plan. This is useful when the drug was offered, but the mutation report, timing, risks, or alternatives are not clear.

Bring the pathology, ER/PR/HER2 results, molecular report, prior treatment list, recent scans, blood tests, sugar history, current symptoms, and the full medicine list. A short timeline helps more than a pile of files with no order.

TAMC does not prescribe this treatment remotely and does not replace the treating doctor. The consultation helps the patient and family understand the medical logic before the next step.

Frequently asked questions – answered by Dr. Stefanska

1. Is capivasertib chemotherapy?

No. I would not call it chemotherapy. Capivasertib is a targeted tablet. It works on the AKT part of a growth route that matters in some breast cancers.

Still, I do not call it an easy tablet. Diarrhea, rash, blood sugar, mouth sores, weakness, and blood tests all need watching. Home tablets can still be serious treatment.

2. Why do PIK3CA, AKT1, and PTEN matter?

Because they tell us whether this route is really part of the cancer story. Without that information, the drug choice becomes guesswork.

I want the full report. Not a screenshot with one mutation word. I need to see what was tested, when it was tested, and whether the result fits the disease now.

3. Can Truqap be used if the patient has diabetes?

Sometimes, but not casually. I need to know the glucose numbers, HbA1c, diabetes medicines, and how stable the patient has been.

If sugar is already high, the first step may be an endocrine plan for the diabetes, not the cancer tablet. Starting without a sugar plan is how trouble begins.

4. What should the patient do if diarrhea starts?

Report it early. Count the stools. Say whether drinking is still possible. Mention dizziness, dry mouth, fever, belly pain, or blood.

Do not wait three days just to be brave. The team may add medicine, fluids, tests, a pause, or a dose discussion. The earlier the call, the more choices there are.

5. Is rash expected or dangerous?

A mild rash can happen. But I still want to know. A photo is often useful.

Painful skin, blisters, peeling, sores in the mouth, fever, or fast spreading is different. That is not a “watch and wait” situation at home.

6. What documents are needed for a Truqap consultation?

Bring the biopsy report, ER/PR/HER2 results, full molecular test, recent scans, blood work, glucose and HbA1c, and the list of all old treatments with dates.

Also bring the current medicine list and a short timeline: diagnosis, surgery if done, endocrine treatments, CDK4/6 treatment if used, progression dates, side effects, and why capivasertib is being discussed now.

7. What if one country offers Truqap and another does not?

That can happen. Access rules, local protocols, test availability, and risk judgment are not always the same.

I would not turn that into “one doctor is right and one is wrong.” I would compare the facts: receptor status, molecular result, disease speed, previous treatment, sugar risk, skin risk, and other real options.

8. If metastases do not shrink quickly, does that mean failure?

Not always. In some cases, stable disease is a useful result, especially if the cancer was moving before.

But stable has to be real. Scans at the right time, symptoms, blood tests, and daily function all matter. If pain grows or new spots appear, the plan needs a new discussion.

Important information

This page gives general medical information only. It is not a treatment prescription. Capivasertib is discussed only after review of the breast cancer subtype, molecular report, previous treatment, blood sugar, organ function, symptoms, medicines, and general condition.

Do not start, stop, restart, or change treatment without the treating doctor.

Contacts

For a consultation about capivasertib:

📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108